Search alternatives:
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 5,681 - 5,700 results of 60,155 for search '(( 5 ((we decrease) OR (nn decrease)) ) OR ( 50 ((teer decrease) OR (a decrease)) ))', query time: 1.06s Refine Results
  1. 5681
    Sema3a inhibits the differentiation of Raw264.7 cells to osteoclasts under 2Gy radiation by reducing inflammation

    Sema3a inhibits the differentiation of Raw264.7 cells to osteoclasts under 2Gy radiation by reducing inflammation by Bo Huang (30906)

    Published 2018
    “…Raw264.7 cells were divided into four groups: A, receiving no radiation; B, receiving no radiation + 50ngng/ml Sema3a; C, receiving 2Gy radiation; and D, receiving 2Gy radiation +50ngng/ml Sema3a. …”
    Save to List
    Saved in:
  2. 5682
    The changes of EFR3A expression in the organ of Corti in the animals treated with kanamycin and furosemide by western blotting.

    The changes of EFR3A expression in the organ of Corti in the animals treated with kanamycin and furosemide by western blotting. by Chen Nie (686387)

    Published 2015
    “…<p>TUJ1 protein, with a molecular weight of 50 KD, was identified as an internal reference. …”
    Save to List
    Saved in:
  3. 5683
    Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments

    Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments by Stefania Ferro (76724)

    Published 2018
    “…The crystal structures of TyBm with inhibitor <b>3</b> (IC<sub>50</sub> value of 25.11 μM) and <b>16</b> (IC<sub>50</sub> value of 5.25 μM) were solved, confirming the binding poses hypothesized by in silico studies and revealing the main molecular determinants for the binding recognition of the inhibitors.…”
    Save to List
    Saved in:
  4. 5684
    Table_5_The non-canonical inflammasome activators Caspase-4 and Caspase-5 are differentially regulated during immunosuppression-associated organ damage.docx

    Table_5_The non-canonical inflammasome activators Caspase-4 and Caspase-5 are differentially regulated during immunosuppression-associated organ damage.docx by Mohamed Ghait (17523321)

    Published 2023
    “…We report that CASP4 and CASP5 are differentially regulated during acute-on-chronic liver failure and sepsis-associated immunosuppression, suggesting non-redundant functions in the inflammasome response to infection. …”
    Save to List
    Saved in:
  5. 5685
    Investigate Pathogenic Mechanism of TXNDC5 in Rheumatoid Arthritis

    Investigate Pathogenic Mechanism of TXNDC5 in Rheumatoid Arthritis by Lin Wang (11986)

    Published 2013
    “…We previously detected increased TXNDC5 expression in synovial tissues and blood from RA patients and demonstrated that the gene encoding TXNDC5 increased RA risk. …”
    Save to List
    Saved in:
  6. 5686
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  7. 5687
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  8. 5688
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  9. 5689
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  10. 5690
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  11. 5691
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  12. 5692
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  13. 5693
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  14. 5694
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  15. 5695
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  16. 5696
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  17. 5697
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  18. 5698
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  19. 5699
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:
  20. 5700
    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer

    Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

    Published 2024
    “…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC<sub>50</sub> = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”
    Save to List
    Saved in:

Search Tools: